ASH: Carfilzomib Ups Survival in Relapsed Multiple Myeloma

This article originally appeared here.
Share this content:
ASH: Carfilzomib Ups Survival in Relapsed Multiple Myeloma
ASH: Carfilzomib Ups Survival in Relapsed Multiple Myeloma

MONDAY, Dec. 8, 2014 (HealthDay News) -- The addition of carfilzomib to lenalidomide and dexamethasone improves progression-free survival in patients with relapsed multiple myeloma, according to a study published online Dec. 6 in the New England Journal of Medicine. The findings were released to coincide with the annual meeting of the American Society of Hematology, held from Dec. 6 to 9 in San Francisco.

A. Keith Stewart, M.B., Ch.B., from the Mayo Clinic in Scottsdale, Ariz., and colleagues randomized 792 patients with relapsed multiple myeloma to carfilzomib with lenalidomide and dexamethasone (carfilzomib group) or lenalidomide and dexamethasone alone (control group).

The researchers found that progression-free survival was significantly improved for the carfilzomib group versus the control group (median, 26.3 versus 17.6 months; hazard ratio for progression or death, 0.69: P = 0.0001). At the interim analysis, the median overall survival was not reached in either group. The 24-month overall survival rates were 73.3 percent in the carfilzomib group and 65.0 percent in the control group (hazard ratio for death, 0.79; P = 0.04). The rates of overall response (partial or better) were 87.1 percent in the carfilzomib group and 66.7 percent in the control group (P < 0.001). Grade 3 or higher adverse events were reported in 83.7 percent of the carfilzomib group and in 80.7 percent of the control group.

"The addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk-benefit profile," the authors write.

The study was supported by Onyx Pharmaceuticals, which manufactures carfilzomib and funded the scientific review of the manuscript; medical writing assistance was provided by BlueMomentum.

Abstract
Full Text
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

WPSI Recommends Annual Urinary Incontinence Screening

WPSI Recommends Annual Urinary Incontinence Screening

Due to limited evidence, other experts urge caution in implementing guideline for women

Young, Growing Athletes at High Risk for ACL Injuries

Young, Growing Athletes at High Risk for ACL ...

Athletic teams should provide program that includes muscle strengthening, proper technique training

Side Effects of Biologics for Rheumatic Dz May Up Anxiety

Side Effects of Biologics for Rheumatic Dz May ...

Common patient concerns are risks of cancer and tuberculosis activation

is free, fast, and customized just for you!




Already a member?

Sign In Now »